$1000 | SAVE $250 | Single User
$1750 | SAVE $750 | Site License
$2400 | SAVE $1,600 | Enterprise License

Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2017 [Report Updated: 31-07-2017]

Published by Delve Insight: 31 Jul 2017 | 116058 | In Stock

Introduction

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Pancreatic Ductal Adenocarcinoma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Pancreatic Ductal Adenocarcinoma by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight`s team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the report

• The report provides a snapshot of the pipeline development for the Pancreatic Ductal Adenocarcinoma

• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Pancreatic Ductal Adenocarcinoma

• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Pancreatic Ductal Adenocarcinoma

• The report also covers the dormant and discontinued pipeline projects related to the Pancreatic Ductal Adenocarcinoma


Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across this Pancreatic Ductal Adenocarcinoma to formulate effective R&D strategies

• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Pancreatic Ductal Adenocarcinoma therapeutics

• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Table of Contents
for Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2017 [Report Updated: 31-07-2017]

  • 1. Report Introduction

    2. Pancreatic Ductal Adenocarcinoma Overview

    3. Pipeline Therapeutics

    • An Overview of Pipeline Products for Pancreatic Ductal Adenocarcinoma

    4. Comparative Analysis

    5. Products in Clinical Stage

    5.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    6. Products in Pre-Clinical and Discovery Stage

    6.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    7. Therapeutic Assessment

    • Assessment by Route of Administration

    • Assessment by Stage and Route of Administration

    • Assessment by Molecule Type

    • Assessment by Stage and Molecule Type

    8. Inactive Products

    8.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    Appendix

    Report Methodology

    Consulting Services

    Disclaimer

    About DelveInsight

List Of Tables
in Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2017 [Report Updated: 31-07-2017]

Table 1:Total Products for Pancreatic Ductal Adenocarcinoma

Table 2: Products in Clinical Stage

Table 3: Products in Pre-Clinical and Discovery Stage

Table 4: Assessment by Route of Administration

Table 5: Assessment by Stage and Route of Administration

Table 6: Assessment by Molecule Type

Table 7: Assessment by Stage and Molecule Type

Table 8: Inactive Products

List Of Figures, Charts and Diagrams
in Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2017 [Report Updated: 31-07-2017]

Figure 1:Total Products for Pancreatic Ductal Adenocarcinoma

Figure 2: Products in Clinical Stage

Figure 3: Products in Pre-Clinical and Discovery Stage

Figure 4: Assessment by Route of Administration

Figure 5: Assessment by Stage and Route of Administration

Figure 6: Assessment by Molecule Type

Figure 7: Assessment by Stage and Molecule Type

Figure 8: Inactive Products

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

116058 | DIPI0255

Number of Pages

50

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Pancreatic Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Pancreatic Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Pancreatic Beta-Cell Protection - Hot Targets & Pipeline Analysis
“Pancreatic Beta-cell Protection Hot Targets & Pipeline Analysis” gives comprehensive insight on the...
12 Aug 2016 by IQ4I USD $3,600 More Info
Pancreatic Cancer Global Clinical Trials Review, H1, 2016
Pancreatic Cancer Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, ...
31 May 2016 by Global Data USD $2,500 More Info
Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan
The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 million by 2021, at...
19 May 2016 by MarketsandMarkets USD $4,650 More Info
Pancreatic Fistula Global Clinical Trials Review, H1, 2016
Pancreatic Fistula Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report,...
11 Mar 2016 by Global Data USD $2,500 More Info
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds...
01 Dec 2015 by GBI Research USD $4,995 More Info
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds...
01 Dec 2015 by GBI Research USD $4,995 More Info
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class InnovationSummar...
01 Jun 2015 by GBI Research USD $6,995 More Info
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class InnovationSummar...
01 Jun 2015 by GBI Research USD $6,995 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2017 [Report Updated: 31-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data